These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 6204221)

  • 61. Systemic T cell adoptive immunotherapy of malignant gliomas.
    Plautz GE; Barnett GH; Miller DW; Cohen BH; Prayson RA; Krauss JC; Luciano M; Kangisser DB; Shu S
    J Neurosurg; 1998 Jul; 89(1):42-51. PubMed ID: 9647171
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model.
    Nakamura K; Ito Y; Kawano Y; Kurozumi K; Kobune M; Tsuda H; Bizen A; Honmou O; Niitsu Y; Hamada H
    Gene Ther; 2004 Jul; 11(14):1155-64. PubMed ID: 15141157
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Cellular immunotherapy for malignant gliomas.
    Lin Y; Okada H
    Expert Opin Biol Ther; 2016 Oct; 16(10):1265-75. PubMed ID: 27434205
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Angiocentric glioma transformed into anaplastic ependymoma: Review of the evidence for malignant potential.
    McCracken JA; Gonzales MF; Phal PM; Drummond KJ
    J Clin Neurosci; 2016 Dec; 34():47-52. PubMed ID: 27742374
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Interleukin-23-expressing bone marrow-derived neural stem-like cells exhibit antitumor activity against intracranial glioma.
    Yuan X; Hu J; Belladonna ML; Black KL; Yu JS
    Cancer Res; 2006 Mar; 66(5):2630-8. PubMed ID: 16510582
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Dendritic cell therapy for malignant glioma].
    Yamanaka R; Homma J; Yajima N; Tsuchiya N; Tanaka R
    No To Shinkei; 2003 Sep; 55(9):771-80. PubMed ID: 14571839
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Immunotherapy with stimulated autologous lymphocytes in a case of a juvenile anaplastic glioma.
    Thomas C; Schober R; Lenard HG; Lumenta CB; Jacques DB; Wechsler W
    Neuropediatrics; 1992 Jun; 23(3):123-5. PubMed ID: 1641079
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Antitumor activity against established intracerebral gliomas exhibited by cytotoxic T lymphocytes, but not by lymphokine-activated killer cells.
    Holladay FP; Heitz T; Wood GW
    J Neurosurg; 1992 Nov; 77(5):757-62. PubMed ID: 1403119
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Eradication of rat malignant gliomas by retroviral-mediated, in vivo delivery of the interleukin 4 gene.
    Benedetti S; Bruzzone MG; Pollo B; DiMeco F; Magrassi L; Pirola B; Cirenei N; Colombo MP; Finocchiaro G
    Cancer Res; 1999 Feb; 59(3):645-52. PubMed ID: 9973213
    [TBL] [Abstract][Full Text] [Related]  

  • 70. In vivo and in vitro effect of adoptive immunotherapy of experimental murine brain tumors using lymphokine-activated killer cells.
    Takai N; Tanaka R; Yoshida S; Hara N; Saito T
    Cancer Res; 1988 Apr; 48(8):2047-52. PubMed ID: 3258182
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Remote results of combination therapy of brain neoplasms in children].
    Ignat'eva IA; Badmaev KN; Smirnov RV
    Med Radiol (Mosk); 1972 Nov; 17(11):8-11. PubMed ID: 4632922
    [No Abstract]   [Full Text] [Related]  

  • 72. Elimination of regulatory T cells is essential for an effective vaccination with tumor lysate-pulsed dendritic cells in a murine glioma model.
    Grauer OM; Sutmuller RP; van Maren W; Jacobs JF; Bennink E; Toonen LW; Nierkens S; Adema GJ
    Int J Cancer; 2008 Apr; 122(8):1794-802. PubMed ID: 18076066
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The new kid on the block: suicide gene therapy to modulate cancer immunosurveillance for children with high-risk malignant brain tumors.
    Sait SF; Karajannis MA
    Neuro Oncol; 2019 Mar; 21(4):419-420. PubMed ID: 30852609
    [No Abstract]   [Full Text] [Related]  

  • 74. Induction of human glioma-specific cytotoxic T-lymphocyte lines by autologous tumor stimulation and interleukin 2.
    Miyatake S; Handa H; Yamashita J; Yamasaki T; Ueda M; Namba Y; Hanaoka M
    J Neurooncol; 1986; 4(1):55-64. PubMed ID: 3489081
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [A new experimental approach to the specific adoptive immunotherapy for malignant gliomas].
    Yamasaki T
    Nihon Geka Hokan; 1983 Nov; 52(6):783-801. PubMed ID: 6331809
    [No Abstract]   [Full Text] [Related]  

  • 76. An experimental approach to specific adoptive immunotherapy for malignant brain tumors.
    Yamasaki T; Kikuchi H
    Nihon Geka Hokan; 1989 Nov; 58(6):485-92. PubMed ID: 2519184
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Cellular immunotherapy for malignant glioma].
    Okamoto Y; Yamashita J
    Nihon Rinsho; 2005 Sep; 63 Suppl 9():557-62. PubMed ID: 16201581
    [No Abstract]   [Full Text] [Related]  

  • 78. T cell adoptive immunotherapy of newly diagnosed gliomas.
    Plautz GE; Miller DW; Barnett GH; Stevens GH; Maffett S; Kim J; Cohen PA; Shu S
    Clin Cancer Res; 2000 Jun; 6(6):2209-18. PubMed ID: 10873070
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [A new experimental approach to the specific immunotherapy for malignant brain tumor. Immunobiological characterization of T-cell growth factor].
    Yamasaki T; Taguchi M; Namba Y; Hanaoka M; Miyatake S; Yamashita J; Handa H
    Neurol Med Chir (Tokyo); 1983 Dec; 23(12):909-16. PubMed ID: 6204221
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.